BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15735816)

  • 1. "ProC Global": a functional screening test that predicts recurrent venous thromboembolism.
    Grand'Maison A; Bates SM; Johnston M; McRae S; Ginsberg JS
    Thromb Haemost; 2005 Mar; 93(3):600-4. PubMed ID: 15735816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An abnormal ProC Global test result is associated with an increased risk of venous thromboembolism independent of test sensitivity for protein C pathway abnormalities.
    Toulon P; Perez P; Rapp J; Adda R
    Thromb Haemost; 2007 Jul; 98(1):228-33. PubMed ID: 17598017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of ProC Global assay in women with a history of venous thromboembolism on hormonal therapy.
    Sarig G; Aberbach I; Schliamser L; Blumenfeld Z; Brenner B
    Thromb Haemost; 2006 Nov; 96(5):578-83. PubMed ID: 17080213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ProC global: a new automated screening assay for the evaluation of total function of the protein C system.
    Dragoni F; Tormene D; Simioni P; Arcieri P; Avvisati G; Girolami A
    Clin Appl Thromb Hemost; 2001 Oct; 7(4):351-5. PubMed ID: 11697723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of the ProC global assay for protein C pathway abnormalities. clinical experience in 899 unselected patients with venous thromboembolism.
    Toulon P; Adda R; Perez P
    Thromb Res; 2001 Oct; 104(2):93-103. PubMed ID: 11672753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact of the introduction of the ProC Global assay in the screening strategy of protein C pathway abnormalities in unselected patients with a history of venous thromboembolism.
    Toulon P; Adda R; Perez P
    Thromb Haemost; 2001 Aug; 86(2):720-1. PubMed ID: 11522035
    [No Abstract]   [Full Text] [Related]  

  • 7. Prediction of recurrent venous thromboembolism by measuring ProC Global.
    Eichinger S; Hron G; Hirschl M; Bialonczyk C; Minar E; Kollars M; Kyrle PA
    Thromb Haemost; 2007 Dec; 98(6):1232-6. PubMed ID: 18064319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ProC Global assay in the evaluation of women with history of severe preeclampsia or HELLP syndrome.
    Heilmann L; von Tempelhoff GF; Pollow K
    Clin Appl Thromb Hemost; 2002 Oct; 8(4):319-24. PubMed ID: 12518722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay. Results of a European multicenter evaluation.
    Toulon P; Halbmeyer WM; Hafner G; Schmitt Y; Randgard B; Odpadlik M; Van Den Eynden C; Wagner C
    Blood Coagul Fibrinolysis; 2000 Jul; 11(5):447-54. PubMed ID: 10937806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
    Santamaria MG; Agnelli G; Taliani MR; Prandoni P; Moia M; Bazzan M; Guazzaloca G; Ageno W; Bertoldi A; Silingardi M; Tomasi C; Ambrosio GB;
    Thromb Res; 2005; 116(4):301-6. PubMed ID: 16038714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro CR global: an effective screening test for thrombophilia.
    Gupta PK; Ahmed R; Kannan M; Dwivedi SN; Choudhry VP; Saxena R
    Am J Hematol; 2003 Nov; 74(3):208-10. PubMed ID: 14587054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
    Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
    Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The reduced sensitivity of the ProC Global test in protein S deficient subjects reflects a reduction in the associated thrombotic risk.
    Gemmati D; Serino ML; Tognazzo S; Ongaro A; Moratelli S; Gilli G; Forini E; De Mattei M; Scapoli GL
    Blood Coagul Fibrinolysis; 2001 Dec; 12(8):691-7. PubMed ID: 11734670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
    Sonnevi K; Tchaikovski SN; Holmström M; Rosing J; Bremme K; Lärfars G
    Thromb Haemost; 2011 Nov; 106(5):901-7. PubMed ID: 21947267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for risk factors for thrombosis using a new generation of assays developed to evaluate the functionality of the protein C anticoagulant pathway.
    Toulon P; Perez P
    Hematol Oncol Clin North Am; 2000 Apr; 14(2):379-89. PubMed ID: 10806561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
    Strandberg K; Svensson PJ; Ohlin AK
    Thromb Res; 2007; 121(2):145-51. PubMed ID: 17499343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ProC Global: the first functional screening assay for the complete protein C pathway.
    Dati F; Hafner G; Erbes H; Prellwitz W; Kraus M; Niemann F; Noah M; Wagner C
    Clin Chem; 1997 Sep; 43(9):1719-23. PubMed ID: 9299966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical usefulness of global assays of the anticoagulant pathway of protein C].
    Toulon P
    Ann Biol Clin (Paris); 2001; 59(5):545-50. PubMed ID: 11602384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.
    Palareti G; Legnani C; Cosmi B; Valdré L; Lunghi B; Bernardi F; Coccheri S
    Circulation; 2003 Jul; 108(3):313-8. PubMed ID: 12847064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy.
    Lowe G; Woodward M; Vessey M; Rumley A; Gough P; Daly E
    Thromb Haemost; 2000 Apr; 83(4):530-5. PubMed ID: 10780311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.